Syngenta may be template as Novartis reviews non-core assets

ZURICH (Reuters) - Novartis may take a leaf out of its past deal-book as the Swiss drugmaker conducts a review into some of its underperforming businesses, a board member said.
Read the full story: Reuters: Health News